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Case Study:
The patient is a 62-year-old male with a 
history of cerebrovascular disease and 
hypertension. He had a recent 
Cerebrovascular Accident (CVA) and was 
found to have a PFO.
Pre-Op Imaging Studies:
CT with intravenous contrast:
• Used to determine size and shape of 
defect. (Pathan, 2018)
No malignancy identified in the chest, 
abdomen or pelvis. No concerning findings.
Transesophageal Echocardiogram (TEE):
• Used to evaluate the atrial septum before, 
during and after the procedure. (Pathan, 2018) 
The patient was considered for a PFO 
closure device due to his recurrent 
cryptogenic strokes. All other test performed 
were considered normal.
PFO device insertion:
The patient was given mild sedation and a 
local anesthesia to both groins. Vascular 
access was obtained in both femoral veins. A 
Swan-Ganz Catheter was introduced to 
evaluate right heart pressures and blood 
saturations. A 5 Fr multipurpose catheter was 
used to cross the PFO and was positioned in 
the pulmonary vein. The catheter was replaced 
with a 9 Fr sheath and advanced across the 
defect with an Amplatzer wire. The PFO was 
evaluated with a sizing balloon to determine 
what size device would be used. (Kern, 2016)
After sizing the defect, a 25 mm Amplatzer PFO 
occluder device was prepared and passed 
through the delivery sheath. The left atrial disk 
was deployed, and the right atrial disk was 
deployed. Fluoroscopy and an intracardiac 
echo were used to determine correct 
placement. The Minnesota Wiggle Test was 
also performed to determine accurate 
placement and sizing.
The Minnesota Wiggle Test is performed to 
ensure the device is stable enough to be 
released. The physician gently pushes forward 
and pulls backwards on the Amplatzer wire. 
Successful placement is determined by the 
lack of movement of the device in either 
direction. (Kern, 2016) 
The device is released off the delivery wire 
using a pin vise, rotating the wire in a 
counterclockwise motion. (Kern, 2016) 
The device was detached and a bubble study 
with Valsalva maneuver  was performed to 
assess for shunting. (Kern, 2016)
PFO Device deployed:
Post procedure patient care:
The long 9 Fr sheath was replaced with a short 
9 Fr sheath and secured with a figure of 8-
stitch to be removed later
• Limited TEE study before discharge
• no atrial shunt demonstrated 
• Infective endocarditis prophylaxis for at 
least 6- 12 months 
• Recommended 81 mg of Aspirin per day 
indefinitely. 
• Recommended Clopidogrel 75 mg at least 3 
months.
• Follow-up TEE appointment at 3 months. If 
closure is complete, Plavix may be stopped. 
Conclusion:
There are several treatment options used to 
treat cryptogenic strokes in patients who have 
a patent foramen ovale. Open surgical 
procedures prove to be unnecessary due to 
the harm it can cause to patient. Medical drug 
therapy alone still puts the patients at risk to 
have recurrent ischemic strokes because the 
physical problem is not being treated. PFO 
closure devices when combined with medical 
drug therapies have been found to 
significantly impact the rate of recurrent 
cryptogenic strokes in PFO patients. 
Because of the success in the RESPECT Trial, 
the FDA approved the PFO occluder as a 
viable  treatment option on October 28, 2016. 
(Mojadidi, 2018)
This option is continuously being studied in 
attempt to further advance it making  it more 
effective for future patients. This life saving 
treatment significantly improves the quality of 
life for  recurrent cryptogenic stroke patients. 
Introduction:
A patent foramen ovale (PFO) is a hole in the 
atrial septum used for fetal circulation. After 
birth, this hole usually closes to increase blood 
pressures within the heart. In 25% of the world’s 
population, the septum never fully closes.  A 
PFO causes a right to left shunt where emboli 
can travel from the venous side to the arterial 
side causing a stroke. Cryptogenic strokes are 
unexplained in origin but may be caused by a 
PFO. (Kern, 2016)
Treatment Options:
Surgical Closure requires a thoracotomy and 
cardiopulmonary bypass. This treatment option 
is rarely chosen, unless the patient is already 
receiving another open cardiovascular 
procedure.  73% of the surgical patient’s still 
have recurrent cryptogenic strokes due to 
incomplete PFO closure. (Saver, 2018)
PFO DEVICE:
The Amplatzer device is a double-disk nitinol 
mesh and polyester fiber device that sits on 
either side of the septal defect. (Kern, 2016)  
This design has caused significantly less 
complications than other devices.(Saver, 2018) 
Drug Therapy Compared to Device Closure
Six randomized clinical trials  were conducted 
comparing medical drug therapies to a PFO 
closure device. Each trial looked at different 
combinations of treatment options with different 
drug therapies and devices. (Saver, 2018)
The RESPECT Trial conducted in 2013 was the 
first trial that showed a significant impact in 
reducing recurrent cryptogenic strokes by 45 
percent, making the closure device the standard 
of treatment. (Saver, 2017) 
Trials conducted from 2017 to 2018 such as the 
DEFENSE-PRO Trial further developed PFO 
device  methods over medical drug therapy 
alone. It was found to be more significant for 
patient’s who have an aneurysmal atrial septum 
and a PFO. (Saver, 2018) 
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The image above demonstrates the sizing balloon 
measuring the size and shape of the defect 
The Image above depicts the deployed closure device
The image above demonstrates a PFO closure device
https://www.openpr.com/news/1031493/global-pfo-closure-device-market-poised-to-take-off-by-2023.html
The image above demonstrates  the atrial septal 
defect.  This image shows a mildly aneurysmal 
atrial septum and no mass or thrombus present 
on atrial appendage.
The Image above demonstrates a presence of a small 
right to left shunt through the PFO while at rest by 
saline contrast injection. 
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